Cited by 164Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomics

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

Open access

Liudahl, Shannon M., Betts, Courtney B., Sivagnanam, Shamilene, Morales-Oyarvide, Vicente, da Silva, Annacarolina, Yuan, Chen, Hwang, Samuel, Grossblatt-Wait, Alison, Leis, Kenna R., Larson, William, Lavoie, Meghan B., Robinson, Padraic, Dias Costa, Andressa, Väyrynen, Sara A., Clancy, Thomas E., Rubinson, Douglas A., Link, Jason, Keith, Dove, Horton, Wesley, Tempero, Margaret A., Vonderheide, Robert H., Jaffee, Elizabeth M., Sheppard, Brett, Goecks, Jeremy, Sears, Rosalie C., Park, Byung S., Mori, Motomi, Nowak, Jonathan A., Wolpin, Brian M., Coussens, Lisa M.·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-20-0841PMC PMC8338775

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Immunotherapies targeting aspects of T cell functionality are efficacious in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) remains refractory to these treatments. Deeper understanding of the PDAC immune ecosystem is needed to identify additional therapeutic targets and predictive biomarkers for therapeutic response and resistance monitoring. To address these needs, we quantitatively evaluated leukocyte contexture in 135 human PDACs at single-cell resolution by profiling density and spatial distribution of myeloid and lymphoid cells within histopathologically defined regions of surgical resections from treatment-naive and presurgically (neoadjuvant)–treated patients and biopsy specimens from metastatic PDAC. Resultant data establish an immune atlas of PDAC heterogeneity, identify leukocyte features correlating with clinical outcomes, and, through an in silico study, provide guidance for use of PDAC tissue microarrays to optimally measure intratumoral immune heterogeneity. Atlas data have direct applicability as a reference for evaluating immune responses to investigational neoadjuvant PDAC therapeutics where pretherapy baseline specimens are not available. Significance: We provide a phenotypic and spatial immune atlas of human PDAC identifying leukocyte composition at steady state and following standard neoadjuvant therapies. These data have broad utility as a resource that can inform on leukocyte responses to emerging therapies where baseline tissues were not acquired. This article is highlighted in the In This Issue feature, p. 1861

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0841

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2021
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Self-citation
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,212
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,619

Show all 52 references

Research works printed but not linked: 1

Johnson, 2020, An integrated clinical, omic, and image atlas of an evolving metastatic breast cancer, bioRxiv, 2020, 12.03.408500

Sorted by citations

Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Applications of single-cell sequencing in cancer research: progress and perspectives
Lei, Y., Tang, R., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01105-2 · Cited by 610
Spatial profiling technologies illuminate the tumor microenvironment
Elhanani, O., Ben-Uri, R., & Keren, L. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.010 · Cited by 546
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 501
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
Single-cell spatial immune landscapes of primary and metastatic brain tumours
Karimi, E., Yu, M. W., Maritan, S. M., Perus, L. J. M., Rezanejad, M., Sorin, M., Dankner, M., Fallah, P., Doré, S., Zuo, D., et al. (2023) · Nature · doi:10.1038/s41586-022-05680-3 · Cited by 401
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
Caronni, N., Terza, F. L., Vittoria, F. M., Barbiera, G., Mezzanzanica, L., Cuzzola, V., Barresi, S., Pellegatta, M., Canevazzi, P., Dunsmore, G., et al. (2023) · Nature · doi:10.1038/s41586-023-06685-2 · Cited by 418
Single-cell spatial landscapes of the lung tumour immune microenvironment
Sorin, M., Rezanejad, M., Karimi, E., Fiset, B., Desharnais, L., Perus, L. J. M., Milette, S., Yu, M. W., Maritan, S. M., Doré, S., et al. (2023) · Nature · doi:10.1038/s41586-022-05672-3 · Cited by 395
Managing the TME to improve the efficacy of cancer therapy
Bilotta, M. T., Antignani, A., & FitzGerald, D. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954992 · Cited by 328
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 224
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin
Ruf, B., Bruhns, M., Babaei, S., Kedei, N., Ma, L., Revsine, M., Benmebarek, M.-R., Ma, C., Heinrich, B., Subramanyam, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.026 · Cited by 207
Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1047 · Cited by 199
Self-citation
Decoding the tumor microenvironment with spatial technologies
Walsh, L. A., & Quail, D. F. (2023) · Nature Immunology · doi:10.1038/s41590-023-01678-9 · Cited by 199
Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas
Kinker, G. S., Vitiello, G. A. F., Diniz, A. B., Cabral-Piccin, M. P., Pereira, P. H. B., Carvalho, M. L. R., Ferreira, W. A. S., Chaves, A. S., Rondinelli, A. J., Gusmão, A. F., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328697 · Cited by 130
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 134
Self-citation
Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer
Yousuf, S., Qiu, M., von Voithenberg, L. V., Hulkkonen, J., Mačinković, I., Schulz, A. R., Hartmann, D., Mueller, F., Mijatovic, M., Ibberson, D., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.036 · Cited by 124
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Bärthel, S., Falcomatà, C., Rad, R., Theis, F. J., & Saur, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00526-x · Cited by 105
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
Gulhati, P., Schalck, A. P., Jiang, S., Shang, X., Wu, C., Hou, P., Ruiz, S. H., Soto, L. M. S., Parra, E. R., Ying, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00500-z · Cited by 89
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells
Halbrook, C. J., Thurston, G., Boyer, S., Anaraki, C., Jiménez, J. A., McCarthy, A., Steele, N. G., Kerk, S. A., Hong, H. S., Lin, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00463-1 · Cited by 80
Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers
Mi, H., Sivagnanam, S., Betts, C. B., Liudahl, S. M., Jaffee, E. M., Coussens, L. M., & Popel, A. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1190 · Cited by 78
Self-citation
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer
Costa, A. D., Väyrynen, S. A., Chawla, A., Zhang, J., Väyrynen, J. P., Lau, M. C., Williams, H. L., Yuan, C., Morales-Oyarvide, V., Elganainy, D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1125 · Cited by 75
Self-citation
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells
Mahadevan, K. K., LeBleu, V. S., Ramirez, E. V., Chen, Y., Li, B., Sockwell, A. M., Gagea, M., Sugimoto, H., Sthanam, L. K., Tampe, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.025 · Cited by 76
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy
Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 74
Macrophages and T cells in metabolic disorder-associated cancers
Taranto, D., Kloosterman, D. J., & Akkari, L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00743-1 · Cited by 81
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity
Sorin, M., Karimi, E., Rezanejad, M., Yu, M. W., Desharnais, L., McDowell, S. A. C., Doré, S., Arabzadeh, A., Breton, V., Fiset, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005545 · Cited by 68
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy
Hilmi, M., Delaye, M., Muzzolini, M., Nicolle, R., Cros, J. F., Hammel, P. R., Cardot‐Ruffino, V., & Neuzillet, C. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00207-8 · Cited by 75
Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma
Neuzillet, C., Nicolle, R., Raffenne, J., Tijeras‐Raballand, A., Brunel, A., Astorgues‐Xerri, L., Vacher, S., Arbaretaz, F., Fanjul, M., Hilmi, M., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6011 · Cited by 67
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 86
Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
Sivakumar, S., Jainarayanan, A., Arbe-Barnes, E. H., Sharma, P. K., Leathlobhair, M. N., Amin, S., Reiss, D. J., Heij, L. R., Hegde, S., Magen, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55424-2 · Cited by 67
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions
Herting, C. J., Karpovsky, I., & Lesinski, G. B. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09988-w · Cited by 60
Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance
Zou, X., Lin, X., Cheng, H., Chen, Y., Wang, R., Ma, M., Liu, Y., Dai, Z., Tasiheng, Y., Yan, Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006698 · Cited by 56
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology
Lee, S., Kim, G., Lee, J., Lee, A. C., & Kwon, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01941-z · Cited by 58
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
Boelaars, K., Kruijssen, L. J. W., Wang, D., de Winde, C. M., Rodríguez, E., Lindijer, D., Springer, B. O., Àvila, I. V. D. H., de Haas, A. M., Wehry, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007805 · Cited by 48
Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model
Narayanan, J. S. S., Hayashi, T., Erdem, S., McArdle, S., Tiriac, H., Ray, P., Pu, M., Mikulski, Z., Miller, A. M., Messer, K. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006133 · Cited by 45
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer
Sanctis, F. D., Lamolinara, A., Boschi, F., Musiu, C., Caligola, S., Trovato, R., Fiore, A., Frusteri, C., Anselmi, C., Poffe, O., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003549 · Cited by 46
Deployable extrusion bioprinting of compartmental tumoroids with cancer associated fibroblasts for immune cell interactions
Mazzaglia, C., Sheng, Y., Rodrigues, L. N., Lei, I. M., Shields, J. D., & Huang, Y. Y. S. (2023) · Biofabrication · doi:10.1088/1758-5090/acb1db · Cited by 47
Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
Croft, W. D., Pearce, H., Margielewska‐Davies, S., Lim, L., Nicol, S. M., Zayou, F., Blakeway, D., Marcon, F., Powell-Brett, S. F., Mahon, B. S., et al. (2023) · eLife · doi:10.7554/elife.86125 · Cited by 44
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 44
Self-citation
Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer
Karamitopoulou, E., Wenning, A. S., Acharjee, A., Zlobec, I., Aeschbacher, P., Perren, A. A., & Gloor, B. (2023) · Gut · doi:10.1136/gutjnl-2022-329371 · Cited by 42
Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology
Mi, H., Sivagnanam, S., Ho, W. J., Zhang, S., Bergman, D. R., Deshpande, A. M., Baras, A. S., Jaffee, E. M., Coussens, L. M., Fertig, E. J., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae421 · Cited by 38
Self-citation
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 47
Peritumoral TIGIT+CD20+ B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer
Liu, H., Wu, J., Xu, X., Wang, H., Zhang, C., Yin, S., & He, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108735 · Cited by 36
Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer
Li, Y., Chang, R. B., Stone, M. L., Delman, D., Markowitz, K., Xue, Y., Coho, H., Herrera, V. M., Li, J. H., Zhang, L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101397 · Cited by 36
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Oberstein, P. E., Costa, A. D., Kawaler, E. A., Cardot‐Ruffino, V., Rahma, O. E., Beri, N., Singh, H., Abrams, T. A., Biller, L. H., Cleary, J. M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1073 · Cited by 35
Self-citation
Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer
Sussman, J., Kim, N., Kemp, S. B., Traum, D., Katsuda, T., Kahn, B., Xu, J., Kim, I., Eskandarian, C., Delman, D., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2352 · Cited by 32
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems
Lencioni, G., Gregori, A., Toledo, B., Rebelo, R., Immordino, B., Amrutkar, M., Xavier, C. P. R., Kocijancic, A., Pandey, D. P., Perán, M., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.002 · Cited by 32
Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer
Blise, K. E., Sivagnanam, S., Betts, C. B., Betre, K., Kirchberger, N. C., Tate, B. J., Furth, E. E., Costa, A. D., Nowak, J. A., Wolpin, B. M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0873 · Cited by 31
Self-citation
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
Abken, H. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01062-y · Cited by 32
Forecasting cancer: from precision to predictive medicine
Fertig, E. J., Jaffee, E. M., Macklin, P., Stearns, V., & Wang, C. (2021) · Med · doi:10.1016/j.medj.2021.08.007 · Cited by 26
Self-citation
Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities
Bansod, S., Dodhiawala, P. B., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13215481 · Cited by 28
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
Stump, C. T., Roehle, K., Manjarrez‐Orduño, N., & Dougan, S. K. (2021) · Open Biology · doi:10.1098/rsob.210245 · Cited by 28
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma
Wattenberg, M. M., Colby, S., Garrido‐Laguna, I., Xue, Y., Chang, R. B., Delman, D., Lee, J., Affolter, K. E., Mulvihill, S. J., Beg, M. S., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.013 · Cited by 24
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups
Karamitopoulou, E., Andreou, A., de Mortanges, A. P., Tinguely, M., Gloor, B., & Perren, A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0144 · Cited by 24
Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer
Du, W., di Magliano, M. P., & Zhang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682217 · Cited by 22
Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Karamitopoulou, E., Wenning, A. S., Acharjee, A., Aeschbacher, P., Marinoni, I., Zlobec, I., Gloor, B., & Perren, A. A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0368 · Cited by 23
KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer
Suzuki, T., Masugi, Y., Inoue, Y., Hamada, T., Tanaka, M. H., Takamatsu, M., Arita, J., Kato, T., Kawaguchi, Y., Kunita, A., et al. (2022) · Cancer Science · doi:10.1111/cas.15398 · Cited by 21
Application of spatial and single-cell omics in tumor immunotherapy biomarkers
Zhang, C., Feng, H.-R., Zhu, J., & Hong, W. (2025) · LabMed discovery. · doi:10.1016/j.lmd.2025.100076 · Cited by 21
Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment
Finan, J. M., Guo, Y., Goodyear, S. M., & Brody, J. R. (2024) · JCO oncology advances. · doi:10.1200/oa-24-00050 · Cited by 21
The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice
Li, Q., Yang, C., Li, J., Wang, R., Min, J., Song, Y., & Su, H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06778-8 · Cited by 21
Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy
Montagne, J. M., Jaffee, E. M., & Fertig, E. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200660 · Cited by 18
Self-citation
“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”
Kronig, M.-N., Wehrli, M., Salas‐Benito, D., & Maus, M. V. (2023) · Immunological Reviews · doi:10.1111/imr.13273 · Cited by 20
Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 18
Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma
Yoshimura, K., Tsujikawa, T., Mitsuda, J., Ogi, H., Saburi, S., Ohmura, G., Arai, A., Shibata, S., Thibault, G., Chang, Y. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.769534 · Cited by 17
Self-citation
Updates in Immunotherapy for Pancreatic Cancer
Chick, R. C., & Pawlik, T. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216419 · Cited by 17
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 16
Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer
Monte, L. B. D., Clemente, F., Ruggiero, E., Pini, R., Ceraolo, M. G., Lena, M. S., Balestrieri, C., Lazarevic, D., Belfiori, G., Crippa, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104819 · Cited by 16
Spatial immune composition of tumor microenvironment in patients with pancreatic cancer
Zwart, E. S., van Ee, T., Affandi, A. J., Boyd, L. N. C., Rodríguez, E., den Haan, J. M. M., Sarasqueta, A. F., van Grieken, N. C. T., Meijer, L. L., van Kooyk, Y., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03573-6 · Cited by 15
Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
Wattenberg, M. M., & Reiss, K. A. (2021) · Cancers · doi:10.3390/cancers13184716 · Cited by 15
MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling
Ghukasyan, R., Liang, K., Chau, K., Li, L., Chan, C., Abt, E. R., Le, T. M., Park, J. Y., Wu, N., Premji, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3322 · Cited by 14
Self-citation
Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer
Gorchs, L., Moro, C. F., Asplund, E., Oosthoek, M., Solders, M., Ghorbani, P., Sparrelid, E., Rangelova, E. B., Löhr, M. J., & Kaipe, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0405 · Cited by 18
Mapping spatial heterogeneity in gastric cancer microenvironment
Wang, B., Song, B., Li, Y., Zhao, Q., & Tan, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116317 · Cited by 15
MIM-CyCIF: masked imaging modeling for enhancing cyclic immunofluorescence (CyCIF) with panel reduction and imputation
Sims, Z., Mills, G. B., & Chang, Y. H. (2024) · Communications Biology · doi:10.1038/s42003-024-06110-y · Cited by 13
The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
Ma, H., Chen, X., Mo, S., Mao, X., Chen, J., Liu, Y., Lu, Z., Yu, S., & Chen, J. (2023) · Theranostics · doi:10.7150/thno.86547 · Cited by 13
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 15
Identifying the Spatial Architecture That Restricts the Proximity of CD8+ T Cells to Tumor Cells in Pancreatic Ductal Adenocarcinoma
Xia, Y., Ma, J., Yang, X., Liu, D., Zhu, Y., Zhao, Y., Fei, X., Xu, D., & Dai, J. (2024) · Cancers · doi:10.3390/cancers16071434 · Cited by 12
From surfing to diving into the tumor microenvironment through multiparametric imaging mass cytometry
Erreni, M., Fumagalli, M. R., Marozzi, M., Leone, R., Parente, R., D’Anna, R., & Doni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544844 · Cited by 12
PD-1+CD8+ T Cells Proximal to PD-L1+CD68+ Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients
Yang, X., Wang, G., Song, Y., Zhuang, T., Li, Y., Xie, Y., Fei, X., Zhao, Y., Xu, D., & Hu, Y. (2023) · Cancers · doi:10.3390/cancers15051389 · Cited by 12
The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities
Herpels, M., Ishihara, J., & Sadanandam, A. (2023) · The Journal of Pathology · doi:10.1002/path.6171 · Cited by 11
Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma
Groß, N., Zhang, Z., Mitchell, J. T., Charmsaz, S., Hernandez, A., Coyne, E. M., Shin, S. M., Carvajal, D. C. V., Sidiropoulos, D. N., Cho, Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179292 · Cited by 11
Self-citation
Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models
Aksoy, S. A., Earl, J., Grahovac, J., Karakaş, D., Lencioni, G., Sığırlı, S., & Bijlsma, M. F. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.12.003 · Cited by 11
Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression
Ponzo, M., Debesset, A., Cossutta, M., Chalabi‐Dchar, M., Houppe, C., Pilon, C., Nicolás‐Boluda, A., Meunier, S., Raineri, F., Thiolat, A., et al. (2022) · Cancers · doi:10.3390/cancers14174265 · Cited by 12
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Sinha, M., Betts, C. B., Zhang, L., Griffith, M. J., Solman, I. G., Chen, B., Liu, E. V., Tamaki, W., Stultz, J., Marquez, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005425 · Cited by 11
Self-citation
3D multiplexed tissue imaging reconstruction and optimized region of interest (ROI) selection through deep learning model of channels embedding
Burlingame, E. A., Ternes, L., Lin, J., Chen, Y.-A., Kim, E. N., Gray, J. W., Santagata, S., Sorger, P. K., & Chang, Y. H. (2023) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2023.1275402 · Cited by 10
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma
Li, X., Hou, W., Xiao, C., Yang, H., Zhao, C., & Cao, D. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00970-6 · Cited by 10
Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies
Caligola, S., Sanctis, F. D., Canè, S., & Ugel, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.867880 · Cited by 10
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
Mukherjee, S., Antony, A., Patnam, N. G., Trivedi, K. H., Karbhari, A., Bhinder, K. K., Zarrintan, A., Fletcher, J. G., Truty, M. J., Johnson, M. P., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337266 · Cited by 9
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Musiu, C., Lupo, F., Agostini, A., Lionetto, G., Bevere, M., Paiella, S., Carbone, C., Corbo, V., Ugel, S., & Sanctis, F. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341079 · Cited by 9
Pancreatic ductal adenocarcinoma holds unique features to form an immunosuppressive microenvironment: a narrative review
Zhou, Q., Chen, D., Zhang, J., Xiang, J.-F., Zhang, T., Wang, H., & Zhang, Y. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000109 · Cited by 9
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Digomann, D., Heiduk, M., Reiche, C., Glück, J., Kahlert, C., Mirtschink, P., Klimová, A., Bösch, F., Tonn, T., Gaedcke, J., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00459-9 · Cited by 9
Galaxy-ME: A Web-based Software Resource for Interactive Analysis of Multiplex Tissue Imaging DatasetsPreprint
Creason, A., Watson, C., Gu, Q., Persson, D., Sargent, L., Chen, Y., Lin, J., Sivagnanam, S., Wünnemann, F., Nirmal, A. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.18.504436 · Cited by 9
Self-citation
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Gao, Z., Azar, J. H., Zhu, H., Williams-Perez, S. M., Kang, S. W., Marginean, C. E., Rubinstein, M. P., Makawita, S., Lee, H., & Camp, E. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1324093 · Cited by 7
Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies
Srinivasan, D., Gout, J., Kleger, A., & Roger, É. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115697 · Cited by 7
A Randomized Phase II Study: CRS207/GVAX plus Anti–PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
Bever, K. M., Huff, A. L., Danilova, L., Wetzel, M., Tandurella, J. A., Durham, J. N., Wang, T., Lee, J. W., Coyne, E. M., Montagne, J. M., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0545 · Cited by 7
Self-citation
Bispecific T-cell engager therapy for gastrointestinal cancers
Burton, K. A., Metropulos, A. E., Kamath, S. D., Munshi, H. G., & Principe, D. R. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218417 · Cited by 7
Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer
Malchiodi, Z. X., Lekan, A. A., Suter, R. K., Deshpande, A. M., Arslan, S., Lee, A. J., Wang, N., Peran, I., Harris, B. T., Duttargi, A., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1481 · Cited by 9
Quantitative multiplex immunohistochemistry reveals inter-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma
Femel, J., Hill, C. M., Bochaca, I. I., Booth, J. L., Asnaashari, T. G., Steele, M. M., Moshiri, A. S., Do, H., Zhong, J., Osman, I., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328602 · Cited by 7

Authors: Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., Lavoie, M. B., Robinson, P., Dias Costa, A., Väyrynen, S. A., Clancy, T. E., Rubinson, D. A., Link, J., Keith, D., Horton, W., Tempero, M. A., Vonderheide, R. H., Jaffee, E. M., Sheppard, B., Goecks, J., Sears, R. C., Park, B. S., Mori, M., Nowak, J. A., Wolpin, B. M., & Coussens, L. M.
Affiliations: Oregon Health & Science University (US)
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
University of California, San Francisco (US)
University of Pennsylvania (US)
Johns Hopkins University (US)
Corresponding author: Coussens, Lisa M.
ORCID: Liudahl, Shannon M.
Betts, Courtney B.
Sivagnanam, Shamilene
da Silva, Annacarolina
Yuan, Chen
Grossblatt-Wait, Alison
Väyrynen, Sara A.
Clancy, Thomas E.
Rubinson, Douglas A.
Link, Jason
Keith, Dove
Horton, Wesley
Tempero, Margaret A.
Vonderheide, Robert H.
Jaffee, Elizabeth M.
Sheppard, Brett
Goecks, Jeremy
Sears, Rosalie C.
Park, Byung S.
Mori, Motomi
Nowak, Jonathan A.
Wolpin, Brian M.
Coussens, Lisa M.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-03-16
Volume: 11
Issue: 8
Pages: 2014-2031
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-20-0841
PMC: PMC8338775
OpenAlex: W3136861954
Cited by: 164
References: 52
Citations by year: 2026: 31 · 2025: 26 · 2024: 34 · 2023: 40 · 2022: 20 · 2021: 13
FWCI: 9.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Stand Up To Cancer—Lustgarten Foundation Pancreatic Cancer Dream Team Translational Research Grant (SU2C-AACR-DT14-14)
National Institutes of Health (1U01 CA224012, U2C CA233280, R01 CA223150, R01 CA226909, R21 HD099367, UL1TR002369)
National Cancer Institute Human Tumor Atlas Network (U2C CA233280)
NIH (U01 CA210171, P50 CA127003, 1U01 CA224012, U2C CA233280, U54 CA209988, R01 CA196228, R01 CA186241)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords: pancreatic ductal adenocarcinoma, tumor immune microenvironment, leukocyte heterogeneity, myeloid cells, lymphoid cells, neoadjuvant therapy, predictive biomarkers, clinical outcomes, metastatic pancreatic cancer, tissue microarray, single-cell profiling
MeSH terms: Humans, Immunotherapy, Leukocytes, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks